Erasca, Inc. (NASDAQ:ERAS) Receives $20.11 Consensus Target Price from Analysts

Erasca, Inc. (NASDAQ:ERAS) has earned an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $20.1111.

A number of research analysts have weighed in on the company. Mizuho decreased their price objective on Erasca from $28.00 to $26.00 and set an “outperform” rating on the stock in a report on Tuesday, May 12th. Stifel Nicolaus raised their target price on Erasca from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, April 27th. HC Wainwright upped their price objective on shares of Erasca from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Guggenheim lifted their price objective on Erasca from $12.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, March 16th. Finally, Piper Sandler raised their price objective on shares of Erasca from $11.00 to $18.00 and gave the stock an “overweight” rating in a report on Friday, March 13th.

Hedge Funds Weigh In On Erasca

A number of institutional investors and hedge funds have recently made changes to their positions in ERAS. EverSource Wealth Advisors LLC raised its holdings in Erasca by 77.8% during the first quarter. EverSource Wealth Advisors LLC now owns 4,249 shares of the company’s stock worth $69,000 after purchasing an additional 1,859 shares during the last quarter. KBC Group NV purchased a new position in Erasca during the first quarter worth about $81,000. State of Wyoming purchased a new stake in Erasca in the 1st quarter valued at about $95,000. ADAR1 Capital Management LLC acquired a new position in shares of Erasca during the 1st quarter valued at about $162,000. Finally, EntryPoint Capital LLC purchased a new position in shares of Erasca during the 4th quarter worth about $38,000. 67.78% of the stock is owned by institutional investors and hedge funds.

Erasca Price Performance

Shares of ERAS stock opened at $17.92 on Thursday. The company has a market cap of $5.57 billion, a price-to-earnings ratio of -19.27 and a beta of 0.65. The stock’s fifty day moving average price is $13.56 and its 200 day moving average price is $12.13. Erasca has a 1-year low of $1.33 and a 1-year high of $24.28.

Erasca (NASDAQ:ERAS) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.48). As a group, equities research analysts anticipate that Erasca will post -0.61 earnings per share for the current year.

More Erasca News

Here are the key news stories impacting Erasca this week:

• Positive Sentiment: Erasca shareholders approved routine annual meeting items, including reelecting directors and ratifying auditors, which provides some governance stability. Erasca Stockholders Reelect Directors and Ratify Auditors
• Neutral Sentiment: Multiple law firms issued updated reminders about the August 10, 2026 deadline for investors to seek lead-plaintiff status in the existing securities fraud class action, keeping the legal overhang in focus. ERAS DEADLINE: Levi & Korsinsky Reminds Erasca, Inc. Investors of Upcoming Securities Class Action Deadline
• Neutral Sentiment: Additional firms, including Bernstein Liebhard, Rosen, Faruqi & Faruqi, Pomerantz, and others, repeated similar class-action notices, which mainly extend the publicity around the same lawsuit rather than adding new facts. ERASCA, INC. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 10, 2026 TO JOIN SECURITIES CLASS ACTION
• Negative Sentiment: The biggest drag remains the class action tied to allegations that Erasca’s disclosures about ERAS-0015 were misleading after Revolution Medicines accused the company of patent infringement and a patient death was reported following treatment, triggering a sharp selloff and renewed investor fear. Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions

About Erasca

Erasca, Inc is a clinical?stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene?driven and immuno?oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.